These results strongly suggested that a complete loss of VPS34 is not viable in AML cells, thus explaining our inability to obtain sub clones with a complete inhibition of VPS34 using CRISPR/CAS9 technology. This evidence concerns the gene PIK3C3 and acute myeloid leukemia.